Clinical Trial Update: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women [Phase 3]

View source ↗

Summary

Phase 3 trial update on adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen in young women with breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN